Nov 30, 2025, 14:49
Talha Badar ASH25 Key Abstracts to Watch in Acute Lymphoblastic Leukemia
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
“ASH25 Key abstracts to watch in acute lymphoblastic leukemia
Overall Takeaways — ASH 2025 ALL Landscape
Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.
TKI + immunotherapy (blina / InO) emerging as new standard-contenders.
CAR-T earlier in therapy (CR1 consolidation and frontline).
Expanding roles for bispecifics and venetoclax-based combinations in R/R ALL.
MRD (especially NGS-MRD) central to future risk-adapted strategies.”
Discover the latest in Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026